Sorrento Therapeutics. has been granted a patent for aqueous pharmaceutical compositions that enable sustained release of corticosteroids. The compositions, designed for various injection methods, include both insoluble and soluble corticosteroids, along with viscosity enhancers like sodium hyaluronate, to treat inflammation and pain. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of July 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Sustained release corticosteroid compositions for pain treatment
The granted patent US12016867B2 outlines a method for treating inflammation and pain through the intra-articular injection of a specific aqueous pharmaceutical composition. This composition includes both an insoluble and a soluble corticosteroid, specifically salts and esters of dexamethasone, combined with at least one viscosity-enhancing agent, which can be sodium hyaluronate or hyaluronic acid. The viscosity-enhancing agent must have a molecular weight between 1.0 MDa and 2.5 MDa and be present in concentrations ranging from 1.0% w/v to 1.5% w/v. The method emphasizes the importance of the weight or molar ratio of the soluble to insoluble corticosteroid, which can vary from 1:4 to 4:1, with specific claims detailing optimal ratios and viscosities for the composition.
Further claims specify the characteristics of the corticosteroids used, with dexamethasone sodium phosphate as the soluble corticosteroid and dexamethasone acetate as the insoluble counterpart. The patent also details the injection parameters, including the force required for injection, which should be less than 27 N, and the injection rate of approximately 0.5 inches per minute. Additionally, the method allows for repeated injections every 4 to 24 weeks, providing a structured approach to managing inflammation and pain in individuals requiring treatment. The patent thus presents a comprehensive formulation and method aimed at enhancing therapeutic outcomes in patients with joint-related conditions.
To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
